Skipper Bio Med Company Profile

Background

Overview

Skipper Bio Med is a research consultancy established in 2018, dedicated to advancing lung and pancreatic cancer technologies. Operating from the Texas Medical Center, the organization offers pro bono services to academic and industry research groups, aiming to bridge the "valley of death" in research and improve patient outcomes.

Mission and Vision

The mission of Skipper Bio Med is to provide personalized tools and resources to clients, facilitating the translation of promising cancer technologies into clinical practice. Their vision is to enhance patient outcomes by supporting the development of innovative cancer treatments.

Industry Significance

By offering free consultancy services, Skipper Bio Med plays a crucial role in accelerating the commercialization of cancer research, thereby contributing to the global fight against lung and pancreatic cancers.

Key Strategic Focus

Core Objectives

Skipper Bio Med focuses on:

Providing pro bono consultancy to research groups developing lung and pancreatic cancer technologies.

Bridging the gap between research and clinical application to improve patient outcomes.

Areas of Specialization

The consultancy specializes in:

Regulatory strategy development.

Intellectual property (IP) management.

Funding strategy formulation.

Research and development planning.

Technology transfer support.

Key Technologies Utilized

While specific technologies are not detailed, Skipper Bio Med leverages its expertise in regulatory affairs, IP management, and R&D planning to support the commercialization of cancer technologies.

Primary Markets Targeted

The primary focus is on research groups and organizations involved in the development of lung and pancreatic cancer treatments.

Financials and Funding

Funding History

Skipper Bio Med operates as a pro bono consultancy, offering its services free of charge to clients. It is fully supported by a private U.S. family personally impacted by these cancers, ensuring the sustainability of its operations without external funding.

Utilization of Capital

The capital provided by the supporting family is utilized to maintain operations, develop resources, and establish partnerships that enhance the consultancy's ability to support cancer research groups effectively.

Pipeline Development

As a consultancy, Skipper Bio Med does not develop its own pipeline of products. Instead, it focuses on assisting clients in advancing their cancer technologies through various stages of development, from preclinical research to clinical trials.

Technological Platform and Innovation

Proprietary Technologies

Skipper Bio Med does not possess proprietary technologies but utilizes its expertise in regulatory affairs, IP management, and R&D planning to support the commercialization of cancer technologies.

Significant Scientific Methods

The consultancy employs strategic methodologies in:

Regulatory strategy development.

Intellectual property management.

Funding strategy formulation.

Research and development planning.

Technology transfer support.

AI-Driven Capabilities

There is no specific information available regarding the use of AI-driven capabilities within Skipper Bio Med's operations.

Leadership Team

Executive Profiles

Paul A. Kurywchak, PhD – Executive Director

Paul manages overall operations, leads client and partner relationships, and makes major decisions for Skipper Bio Med. He holds a PhD in Cancer Biology from the MD Anderson Cancer Center – UTHealth Graduate School of Biomedical Sciences.

Sanjana Mahapatra, PhD – Strategy Director

Sanjana evaluates the regulatory, IP, and funding status of client technologies and develops tailored strategies for commercialization. She earned her PhD in Immunology from Baylor College of Medicine.

Dustin Srinivas, PhD – Research Director

Dustin leverages his expertise in cancer therapeutics to evaluate the quality and research potential of client technologies. He holds a PhD in Biomedical Sciences and Translational Medicine from Cedars Sinai Medical Center.

Terry McNearney, MD – Senior Consultant

Terry is Board Certified in Internal Medicine and Rheumatology, with experience in basic and clinical research, and has served as a Senior Medical Advisor at Eli Lilly.

Advisory Group

Kevin Coker, JD, MPH, MS – Regulatory Consultant

Co-Founder and CEO of Proxima Clinical Research, with expertise in regulatory strategy.

Wendy K.D. Selig, BA, MSJ – Business Consultant

Founder and CEO of WSCollaborative, specializing in building relationships between nonprofits, industry, and government.

Jim Graham, MBA – Investor

Head of Investments at Research Bridge Partners Catalyst fund, with experience in venture capital and family office investment.

Jeff Bockman, PhD – BioConsultant

Head of the Oncology Practice at Lumanity, with decades of experience in helping companies bring products to market.

Glen Weiss, MD, MBA – Oncologist

Physician scientist and current VP of Clinical Sciences at SOTIO, with extensive experience in phase I clinical trials and translational research.

Market Insights and Competitor Profile

The market for cancer research consultancy services is characterized by a growing demand for specialized support in translating research into clinical applications. Organizations like Skipper Bio Med play a pivotal role in accelerating this process, thereby contributing to the advancement of cancer treatments.

While specific competitors are not extensively detailed, other organizations offering similar consultancy services in the oncology research sector may include entities like Greenlight Guru, which provides a Medical Device Success Platform to support startups navigating medical device development challenges.

Strategic Collaborations and Partnerships

Skipper Bio Med has partnered with organizations such as Greenlight Guru to provide comprehensive support to startups in the medical device development sector. This collaboration aims to streamline the commercialization process for cancer technologies.

Operational Insights and Strategic Opportunities

Skipper Bio Med's unique position as a pro bono consultancy allows it to leverage resources and partnerships from academia, industry, and third-party organizations, providing personalized tools to clients without seeking compensation. The consultancy is well-positioned to expand its network of partnerships, enhance its resource base, and continue supporting the commercialization of innovative cancer treatments, thereby contributing to improved patient outcomes.